A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase I Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
Latest Information Update: 02 Jul 2024
At a glance
- Drugs HF 158K1 (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Colon cancer; Gastric cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions
- Sponsors HighField Biopharmaceuticals
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 28 May 2024 Results presented in the HighField Biopharmaceuticals media release.
- 28 May 2024 According to a HighField Biopharmaceuticals media release, an abstract about trial plan from phase Ia dose escalation portion of this trial will be presented at the American Society of Clinical Oncology annual meeting May 31 to June 4, in Chicago, IL.